Skip to main content

Table 3 Novel agents for the treatment of Pulmonary–renal syndrome [102-113]

From: Bench-to-bedside review: Pulmonary–renal syndromes – an update for the intensivist

Biological agent Mechanism of action Indication-study population Comments
Etanercept TNFα inhibitor Maintenance therapy in Wegener's granulomatosis Not effective, high rate of treatment-related complications
Infliximab TNFα inhibitor ANCA-associated vasculitis Effective, severe infection rate, severe relapse rate
Rituximab Anti-CD20 antibody for B lymphocytes ANCA-associated vasculitis, refractory to or contraindication to treatment Effective, preliminary data
Mycofenolate mofetil Suppressor of B lymphocytes and T lymphocytes ANCA-associated vasculitis, remission maintenance Well tolerated, high relapse rate
Leflunomide Suppressor of T cells Wegener's granulomatosis, remission maintenance Well tolerated, high relapse rate
Antithymocyte globulin Suppressor of T cells Severe refractory Wegener's granulomatosis Partial or complete remission, high complication rate
  1. ANCA, antineutrophil cytoplasmic antibodies.